Listen to The Podcast
Capital Ideas Media President & Publisher Mark Bunting in conversation with Grace Pedota on the Canadian Securities Exchange podcast, #Hashtag Finance. Mark talks about his favourite podcasts, the changing face of business news media, his early days in radio, the difference between covering sports and finance, and they play the word game, Blurt.
Aaron Dunn, Senior Analyst at KeyStone Financial talks to Capital Ideas Media President & Publisher Mark Bunting in the audio version of a recent live stream broadcast. Aaron gives you six growth, dividend and U.S. top picks, and excellent insight into how KeyStone's Canadian Small Cap Growth portfolio has achieved an average annual return of more than 36% since 1998.
Capital Ideas Media publisher Mark Bunting talks to Bruce Campbell, founder and portfolio manager of StoneCastle Investment Management. Bruce manages the Purpose Canadian Equity Growth Fund, which is higher by more than 30% this year, and ranked number one in its category. He also manages the StoneCastle Cannabis Growth Fund, which is up by more than 28% since its launch in September of 2018. Bruce brings you his macro view of the market, five small cap top picks, and answers viewer questions.
Capital Ideas Media publisher Mark Bunting talks to Mark Goliger, the CEO of National Access Cannabis (TSXV:META), the largest cannabis retailer in Canada. Goliger details the company’s expansion plans, its readiness for new products, and why investors should pay attention to the leverage and growth potential of the company.
Capital Ideas Media publisher Mark Bunting talks again with Tyler Robson, CEO of Valens GroWorks (CSE:VGW), the largest cannabis extractor in Canada. The company’s shares have more than doubled since his last visit. Find out about the company’s deals with Canopy Growth, Tilray and other top 10 licensed producers, and why Valens is very well-positioned for “Legalization 2.0” coming in October.
NextLeaf Solutions (CSE:OILS) beat multi-billion dollar public companies to the first U.S. patent for the extraction and purification of cannabinoids. The company has a facility in B.C. ready for “Legalization 2.0” to be a white label provider to many different types of consumer facing cannabis companies. Capital Ideas Media publisher Mark Bunting talks to Paul Pedersen, co-founder and CEO of Nextleaf, who was also a founder of Peace Naturals, which was bought by Cronos Group.
Capital Ideas TV travels to Las Vegas to Planet 13 (CSE:PLTH;OTC:PLNHF), the largest cannabis dispensary in the world. Capital Ideas Media publisher Mark Bunting talks to co-CEO Bob Groesbeck, who gives us a tour and details the company’s ambitious expansion plans for a 40,000 square foot entertainment complex.
Planet 13’s stock has doubled since our first interview last July, and Groesbeck is very confident there is much higher revenue and profit in the future as the company rolls out its concept across the U.S.
Capital Ideas travels to Las Vegas for a wireless conference at the invitation of Siyata Mobile (TSXV:SIM;OTCQCX:SYATF).
The company is kicking into a higher gear after striking distribution deals with AT&T, Motorola, FirstNet and Bell Mobility for its flagship product, the Uniden UV350, the “first and only” push-to-talk over cellular (PoC) device for commercial vehicles.
Hear our conversation with Siyata mobile founder and CEO Marc Seelenfreund as he details why the company’s revenue, earnings and stock price should start to ramp up.
Accord Financial (TSX:ACD) CEO Simon Hitzig talks with Capital Ideas Media publisher Mark Bunting about tripling the company’s loan portfolio, being more diverse than ever, and the record earnings that have resulted from the company’s five-year growth plan.
Capital Ideas Media publisher Mark Bunting sits down with Dr. Jack Regan, founder and CEO of Lexagene Holdings (TSXV:LXG;OTC:LXXGF). The company is on the verge of commercializing its pathogen detection system, which is faster and less expensive than current methods.
Regan says Lexagene has already had exploratory talks with larger biotech firms that need this technology in their product line. That makes a buyout of Lexagene later this year a distinct possibility.